# Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy

- Source: PR Newswire M&A
- Published: 2026-11-05T09:08:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/mondego-bio-initiates-first-in-human-study-of-mb388-an-oral-dual-ptpn2ptpn1-inhibitor-designed-to-overcome-resistance-to-cancer-immunotherapy-302930509.html
- Canonical: https://groundlevelnews.com/story/mondego-bio-initiates-first-in-human-study-of-mb-388-an-oral-dual-ptpn-e7a60f/

Phase 1a study in healthy volunteers will assess safety, pharmacokinetics and pathway engagement; Phase 1b study in patients with advanced solid tumors planned to begin in January 2027 CANTANHEDE, Portugal, Nov. 5, 2026 /PRNewswire/ -- Mondego Bio today announced the initiation of a...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._